Tenax Therapeutics

NEWS

Business

BioSpace Movers & Shakers, Feb. 4

Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

February 3, 2022

9 min read

Alex Keown

Business

New CEOs Named at Two Biopharma Companies

Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.

July 8, 2021

2 min read

Vanessa Doctor, RN

IN THE PRESS

Press Releases

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

November 1, 2024

1 min read

Business

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

August 13, 2024

9 min read

Press Releases

Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

August 12, 2024

8 min read

Business

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 14, 2024

11 min read

Policy

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

April 30, 2024

6 min read

Bio NC

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

April 9, 2024

9 min read

Business

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

March 28, 2024

11 min read

Bio NC

Tenax Therapeutics to Present at the 36th Annual Roth Conference

March 12, 2024

1 min read

Bio NC

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

February 29, 2024

5 min read

Drug Development

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

February 20, 2024

6 min read

JOBS